Salarius Pharmaceuticals receives Nasdaq extension to regain equity compliance by Oct 20, 2025

Decoy Therapeutics Inc.

Nasdaq Hearings Panel granted Salarius until October 20, 2025 to comply with the Equity Standard (Rule 5550(b)(1)).
Salarius effected a 1-for-15 reverse stock split on August 15, 2025, targeting compliance with the $1.00 Minimum Bid Price by August 29, 2025.
Previously received a Delisting Notice on April 23, 2025 for noncompliance with the Minimum Bid Price Requirement.
The extension follows prior milestones, including a previous extension granted on July 28, 2025 for compliance by August 12 (equity) and August 29 (bid price).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.